CoChat

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Open access

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Key Points: EPZ-5676 is a potent DOT1L inhibitor that causes tumor regressions in a rat xenograft model of MLL-rearranged leukemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2013-04-497644

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 744

Metadata

Authors
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., Waters, N. J., Chesworth, R., Moyer, M. P., Copeland, R. A., Richon, V. M., & Pollock, R. M.
Affiliations
  • Epizyme (United States) (US)
  • Epizyme, Inc., Cambridge, MA
Venue
Blood
Published
2013-08-08
Volume
122
Issue
6
Pages
1017-1025
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2104954848
Cited by
722
References
45
Citations by year
2026: 19 · 2025: 37 · 2024: 36 · 2023: 45 · 2022: 54 · 2021: 53 · 2020: 57 · 2019: 72 · 2018: 52 · 2017: 81 · 2016: 62 · 2015: 78 · 2014: 65 · 2013: 8
FWCI
52.10
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
DOT1L, histone methyltransferase inhibition, H3K79 methylation, acute leukemia, MLL translocation, small molecule inhibitors, targeted therapy
MeSH terms
Histone Methyltransferases, Animals, Antineoplastic Agents, Benzimidazoles, Dose-Response Relationship, Drug, Female, Histones, Humans, Leukemia, Methyltransferases, Neoplasm Transplantation, Protein Conformation, Histone-Lysine N-Methyltransferase, Rats, Nude, DNA Methylation, Cell Line, Tumor, Cell Proliferation, Rats, Myeloid-Lymphoid Leukemia Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. https://app.cochat.ai/papers/10.1182/blood-2013-04-497644
The paper
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., Waters, N. J., Chesworth, R., Moyer, M. P., Copeland, R. A., Richon, V. M., & Pollock, R. M. (2013). Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. https://doi.org/10.1182/blood-2013-04-497644

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.